pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,719 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT829Endpoints632BioPharma Dive241onclive165Fierce Biotech93BioSpace91raps37globenewswire health28fda recalls
therapy area
allOncology4989Rare Disease831Hematology761Cardiology717Immunology715Psychiatry & CNS579Pulmonology
  • FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma
    Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.
    onclive · 2mo ago↗ source
  • Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
    Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery. For privately held companies, Isomorphic’s raise is the secon…
    Endpoints · 2mo ago↗ source
  • [177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC
    [177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.
    onclive · 2mo ago
← prev
page 52 of 69
next →
22
fda press21
fda medwatch17
570
Vaccines506
Endocrinology & Metabolism288
Ophthalmology254
Infectious Disease247
Pain232
↗ source
  • Pfizer and Arvinas give disappointing breast cancer drug to Rigel
    Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…
    Endpoints · 2mo ago↗ source
  • FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma
    The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.
    onclive · 2mo ago↗ source
  • STAT+: STAT examines America’s deadliest drug
    STAT examines America's failure to address excessive alcohol use across decades.
    STAT · 2mo ago↗ source
  • Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
    Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…
    Endpoints · 2mo ago↗ source
  • Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
    Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…
    Endpoints · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
    The 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge
    STAT · 2mo ago↗ source
  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 2mo ago↗ source
  • Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
    A startup that spun out of UC Berkeley aims to improve healthcare operations by getting AI to think like a doctor would. Knit Health launched with $11.6 million in seed funding co-led by Uncork Cap…
    Endpoints · 2mo ago↗ source
  • Unmet Needs in Endometrial Cancer
    Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs
    In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that…
    onclive · 2mo ago↗ source
  • Future Directions in Relapsed and Refractory Multiple Myeloma
    onclive · 2mo ago↗ source
  • Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
    Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.
    onclive · 2mo ago↗ source
  • Sequencing Strategies After Progression in Multiple Myeloma
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy
    In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.
    onclive · 2mo ago↗ source
  • Sequencing ADCs in Endometrial Cancer
    Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.
    onclive · 2mo ago↗ source
  • Second Clinical Scenario - Progressive Disease Despite Hematocrit Control
    Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.
    onclive · 2mo ago↗ source
  • STAT+: Capsida says it still doesn’t know what caused gene therapy death
    Some in the gene therapy field lament lost time while Capsida kept silent about the brain receptor it was targeting when things went wrong.
    STAT · 2mo ago↗ source
  • Flagship startup Serif says it has solved non-viral gene therapy in monkeys
    BOSTON — Serif Biomedicines, a startup launched last month by Flagship Pioneering, believes it has solved two technical challenges that have long prevented gene therapy from being delivered without…
    Endpoints · 2mo ago↗ source
  • STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
    As new AI models for predicting sepsis hit the market, experts say performance alone will not drive adoption by hospitals.
    STAT · 2mo ago↗ source
  • Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
    It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bris…
    Endpoints · 2mo ago↗ source
  • PCOS’s new name is PMOS, a small letter change that required a big scientific process
    A revised name for PCOS — polyendocrine metabolic ovarian syndrome, or PMOS — was introduced in a paper published Tuesday.
    STAT · 2mo ago↗ source
  • STAT+: Despite its toll, alcohol is still an awkward subject in the doctor’s office
    Alcohol screening and counseling are too often compressed or skipped during doctor's visits — a gap that is costing patients and the health care system.
    STAT · 2mo ago↗ source